Vesalius, Swisscanto in €19m series-B for OncoDNA

Vesalius is currently investing from its Vesalius Biocapital III fund, a 2017-vintage vehicle that held a final close on €120m in June 2019. The fund invests in later-stage European life-sciences companies in drug development, medtech, diagnostics and digital health with the goal of building a portfolio of 10-15 companies.

The 2018-vintage Swisscanto PE Switzerland Growth I fund was founded by Zürcher Kantonalbank and held a first close on CHF 150m in December 2018. The vehicle has a CHF 200m hard-cap. The fund is looking to provide growth capital to companies in the data services, health, environment and energy sectors. It plans to make 20 investments during its five-year investment period. 

The round also saw participation from SFPI-FPIM. Existing shareholders CPH Bank, Inventures, Sambrinvest, Sofinim (Ackermans & Van Haaren) and SRIW also participated.

The fresh capital will be used for international growth, software development acceleration and hiring initiatives.

Previous funding
In September 2016, OncoDNA closed a €7.7m series-A funding round led by Ackermans & Van Haaren, with participation from existing shareholders IPG and Sambrinvest, as well as new investors SRIW, CPH, and Inventures.

Company
Founded in 2012, OncoDNA is an oncology-focused healthcare technology company that performs cancer diagnosis. The company is based in Gosselies and has 50 employees in four countries. It works with an international network of 35 distributors covering 50 countries.

People
OncoDNA – Jean-Pol Detiffe (founder, CEO).
Vesalius BioCapital – Guy Geldhof (partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• Benelux
• Healthcare
• Belgium
• Venture